Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Ekso Bionics Holdings (EKSO) EBITDA (2016 - 2026)

Ekso Bionics Holdings has reported EBITDA over the past 14 years, most recently at -$4.7 million for Q4 2025.

  • On a quarterly basis, EBITDA fell 89.06% to -$4.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$13.3 million, a 26.74% decrease, with the full-year FY2025 number at -$13.3 million, down 26.74% from a year prior.
  • EBITDA reached -$4.7 million in Q4 2025 per EKSO's latest filing, down from -$1.4 million in the prior quarter.
  • The five-year high for EBITDA was -$1.4 million in Q2 2021, with the low at -$4.7 million in Q4 2025.
  • The 5-year median for EBITDA is -$3.2 million (2021), against an average of -$3.1 million.
  • The largest YoY upside for EBITDA was 88.31% in 2021 against a maximum downside of 183.31% in 2021.
  • Tracing EKSO's EBITDA over 5 years: stood at -$2.6 million in 2021, then plummeted by 55.69% to -$4.1 million in 2022, then rose by 7.56% to -$3.8 million in 2023, then soared by 34.9% to -$2.5 million in 2024, then crashed by 89.06% to -$4.7 million in 2025.
  • According to Business Quant data, EBITDA over the past three periods came in at -$4.7 million, -$1.4 million, and -$3.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.